Clinical factor-based risk stratification for precision therapy in locally advanced squamous cell carcinoma of the uterine cervix

Feng Yuan Liu, Wei Chun Chen, Yu Bin Pan, Chun Chieh Wang, Yun Hsin Tang, Hung Hsueh Chou, Angel Chao, Lan Yan Yang*, Chyong Huey Lai*

*此作品的通信作者

研究成果: 期刊稿件文章同行評審

摘要

BACKGROUND: Concurrent chemoradiotherapy (CCRT) is the standard of care for locally advanced cervical cancer. In this study, we analyzed the pretreatment clinical and 18 F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) characteristics of patients with locally advanced cervical squamous cell carcinoma (SCC) to develop a scoring prototype for risk stratification.

METHODS: Two cohorts were constructed in this study. Cohort 1 comprised patients with cervical SCC with 2009 FIGO stage III-IVA or stage I-II with positive pelvic or para-aortic lymph node (PALN) on PET/CT from AGOG09-001 trial. Cohort 2 comprised patients with similar characteristics who had received adequate therapy in our hospital between 2016 and 2021. Pretreatment patient characteristics and PET/CT parameters including maximum standardized uptake value (SUV max ) and metabolic tumor volume (MTV) of primary tumor and nodal SUV max were assessed for cancer-specific survival (CSS) using multivariate Cox regression.

RESULTS: Analysis of combined data from cohorts 1 (n = 55) and 2 (n = 128) indicated age ≥ 66 years, primary tumor MTV ≥87 mL, and positive PALN on PET/CT to be independently significant adverse predictors for CSS (p < 0.001, p = 0.014, and p = 0.026, respectively) with a median follow-up duration of 51 months. Assigning a score of 1 to each adverse predictor, patients with cumulative risk scores of 0, 1, 2, and 3 were discovered to have a 5-year CSS of 86.9%, 71.0%, 32.2%, and 0%, respectively (p < 0.001).

CONCLUSION: Age, primary tumor MTV, and positive PALN on PET/CT may serve as independent predictors of poor survival in patients with locally advanced cervical SCC. Our findings indicate that patients without any adverse factors can receive standard CCRT, whereas those with at least one adverse factor can consider novel combination therapies or clinical trials.

原文英語
文章編號e6746
期刊Cancer Medicine
13
發行號1
早期上線日期08 01 2024
DOIs
出版狀態已出版 - 01 2024

文獻附註

© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

指紋

深入研究「Clinical factor-based risk stratification for precision therapy in locally advanced squamous cell carcinoma of the uterine cervix」主題。共同形成了獨特的指紋。

引用此